Ge Long Hui A P P·2026-03-16 09:59Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the transfer of the supplementary application for Ezetimibe Tablets, enhancing its product portfolio and competitiveness in the market [1] Group 1: Regulatory Approval - The National Medical Products Administration issued a supplementary application approval notice for Ezetimibe Tablets, allowing the transfer of the marketing authorization holder [1] - The supplementary application for the change of the marketing authorization holder was submitted in February 2026 and accepted, with approval granted in March 2026 [1] Group 2: Product Indications - Ezetimibe Tablets are indicated for the adjunctive treatment of primary hypercholesterolemia, homozygous familial hypercholesterolemia, and sitosterolemia (or plant sterolosis) beyond dietary control [1] Group 3: Strategic Implications - The approval of Ezetimibe Tablets is expected to enrich the company's formulation product series and improve its competitive position in the pharmaceutical market [1]